US › Healthcare

Spero Therapeutics Inc (SPRO)

US · Healthcare · Biotechnology

$1.12+0.90%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Revenue YoY

-100.0%

Net profit

$-9.6M

EPS

$-0.16

EPS estimate

$-0.19

EPS came in at -0.16 against a street estimate of -0.19 — a beat of 15.8%.

Key statistics

Market cap

$65.8M

P/E

8.1

Forward P/E

0.0

P/B

1.49

Book value

$0.76

EPS (TTM)

$0.14

52-week high

$3.08

52-week low

$1.08

50-day MA

$1.38

200-day MA

$2.19

Beta

1.48

Analyst view

Analysts rate Spero Therapeutics Inc a hold (1 buy, 2 hold, 0 sell out of 3) with an average price target of $4.00.

Shareholding

Insiders

22.61%

Institutions

18.22%

Largest institutional holders

Fund	Stake
GSK PLC	15.78%
Pfizer Inc	4.06%
Vanguard Capital Management, LLC	3.09%
Renaissance Technologies Corp	2.04%
Alphabet Inc	1.53%
Geode Capital Management, LLC	0.89%
BlackRock Inc	0.74%
Two Sigma Investments LLC	0.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Spero Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.